Kerri Fitzgerald

DocwireNews

Romosozumab produces “substantial” bone mineral density (BMD) gains at the total hip and lumbar spine within one year of treatment, according to a study published as part of the American College of Rheumatology Annual Meeting. However, treatment sequencing of romosozumab impacts outcomes.
Researchers evaluated the percent change in BMD from baseline at the total hip and lumbar spine from four clinical trials (ARCH, FRAME, STRUCTURE, and a phase II study) in which patients received romosozumab prior to or following an antiresorptive therapy (alendronate or denosumab). Percent change in BMD from baseline was assessed by either an analysis of covariance or repeated measures model adjusting for baseline covariates or as summary statistics.
In the ARCH trial, total hip BMD increased 6.2% following one year of romosozumab and increased a total of 7.1% with the two-year romosozumab/alendronate sequence. For lumbar spine, BMD increased 13.7% with one year of romosozumab and a total of 15.2% with the two-year romosozumab/alendronate sequence.
In the FRAME study, total hip BMD increased 6.8% with one year of romosozumab and a total of 8.8% with the two-year romosozumab/denosumab sequence. For lumbar spine, BMD increased 13.3% with one year of romosozumab and a total of 17.6% with the two-year romosozumab/denosumab sequence.
In the STRUCTURE trial, patients were previously treated for one or more years with alendronate prior to romosozumab. BMD increased 2.9% for total hip and 9.8% for lumbar spine with one year of romosozumab.
In the phase II study, patients were previously treated for one or more years with denosumab prior to romosozumab. For total hip, one year of romosozumab increased BMD by 0.9%, for a total gain of 3.8% with the two-year denosumab/romosozumab sequence. For lumbar spine, one year of romosozumab increased BMD by 5.3%, for a total gain of 11.5% with the two-year denosumab/romosozumab sequence.
“In patients treated with alendronate or denosumab, transition to romosozumab can improve BMD, though gains are not as large as those seen when romosozumab is used first,” the researchers concluded. “Our findings support the concept that high-risk patients should be offered treatment with romosozumab first, followed by transition to a potent antiresorptive.”

Dr. John Fruehauf, Evolent

Advancing Therapies Have Improved the Prognosis of Metastatic Melanoma

Melanoma

Andrew Moreno

Study Assesses Prevalence of Thrombotic Events, Impact on Survival in Patients With New Diagnosis of MM

Thrombosis

Emily Menendez

177Lu-edotreotide Improves PFS, OS Over Everolimus for SSTR-Positive GEP-NETs

GEP-NETs

Latest News

Romosozumab Improves Hip, Lumbar Spine BMD, But Treatment Sequencing Impacts Outcomes

Osteoporosis

Romosozumab produces “substantial” bone mineral density (BMD) gains at the total hip and lumbar spine within one year of treatment, according to a study published as part ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe